about
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow.A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia.Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaHypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma.Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate.RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases.Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma.Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patientsPlasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow : Summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working GrBone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version.A Lucky Mistake: The Splenic Glands of Marcello Malpighi.Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.Pure Erythroid Leukemia Mimicking Ewing Sarcoma/Primitive Neuroectodermal Tumor in an Infant.The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.Issues in diagnosis of small B cell lymphoid neoplasms involving the bone marrow and peripheral blood. Report on the Bone Marrow Workshop of the XVIIth meeting of the European Association for Haematopathology and the Society for Hematopathology.Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter studyHistiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entityChronic myelomonocytic leukemia: The role of bone marrow biopsy immunohistology
P50
Q27853399-44F8998B-20B8-440D-967D-5592541B27BEQ33361703-A6C32974-BBBE-4F01-9A00-5ED7D2B8ABEDQ33437824-B17EF245-1600-422C-8D45-43461D64353AQ33583294-837D7FE3-F93E-41D1-8635-257012F9DB89Q35742364-FAC115F1-4726-4EC4-8E5B-609C56794A6AQ36065290-D403CD85-8E0A-439C-A600-D4746399C202Q36414139-9CC7F745-616E-455F-A9C4-BDD4D715C995Q36681461-4BDBF262-C42E-4264-8804-D3D7D97F5C08Q36857958-3697AFFE-A7BE-41AF-9EAB-D96CCF54BB77Q37332231-5120C8E3-BD53-479F-A451-A69CB648B587Q37610194-1AD83B23-F0A7-457D-806A-6A70EF5753B6Q38220788-6D69F83B-9D46-4D86-89CC-C4C6FF82EFCAQ38689790-4ED8FF57-9957-493E-972F-567882080457Q38830557-B00C2561-9BF3-4D30-AA3D-1B8D00285F31Q39048645-B62083C2-C382-438A-AAF7-3DCC47B5280FQ39770083-1F83286C-9804-4FAD-9BF2-C332549DC391Q40184243-6EBEC05A-BD26-41F1-B22D-FF0FA5C2923BQ40197045-569F1714-D104-4B44-AA0A-43F9554DCE98Q40796551-10B8069B-0860-4FD3-89CC-CECA2C4E439CQ41507351-3E12D059-204B-4CC1-9EF3-2F2DDD4680E3Q42174759-C1575C63-7B3B-4A69-8971-45413E59D50BQ42217211-61BA83FD-5685-4049-B914-F21C8D42A4ACQ42361982-4BFFEB9A-5F9F-4E03-A24C-3FB97ACADE04Q42645612-8ACC6EE8-33E7-4015-99BD-24F3C8161A98Q47094379-39F448F1-D9DF-44D9-BD66-CDA53BC8BDB8Q48205239-82B3CEA6-96E7-4734-BCBD-F7C60E1BB29CQ48327519-85F7D3D1-F74A-40A1-8224-3C84E42C34C1Q49632201-F862D311-DD34-4D74-A2C2-1B2CAC4D284BQ50017231-7B4FD371-B66B-4B10-B06C-77E00F45578DQ50071632-D8CFD1B5-ACA9-4FAA-BA33-CCE4D9281045Q50205498-03324247-1A84-4976-8E28-10931868224EQ52844230-19011CC8-CD28-4A3D-A4E2-9A18FB19B0ABQ52868118-421021AF-8265-4F89-B433-9D5083B640CDQ53098372-36D5EA0D-37EB-4756-AF05-48E86DC92455Q53461061-A5595711-2480-41A3-83D2-BFD3F4C96759Q55068347-247C1752-0E3C-4644-8778-8F061BC08203Q58608043-EFD74A17-367E-4D48-9C07-1D6979BEB3BEQ58798177-1144E017-7810-4E11-B2BB-24B1D68F0468Q67693691-A21FFA07-48D5-443C-AA6F-C0A19E91EAF2Q79241949-82DED41E-1D02-42E6-8CF8-8AB0BD54C251
P50
description
researcher ORCID ID = 0000-0002-1660-7013
@en
wetenschapper
@nl
name
Attilio Orazi
@ast
Attilio Orazi
@en
Attilio Orazi
@es
Attilio Orazi
@nl
type
label
Attilio Orazi
@ast
Attilio Orazi
@en
Attilio Orazi
@es
Attilio Orazi
@nl
prefLabel
Attilio Orazi
@ast
Attilio Orazi
@en
Attilio Orazi
@es
Attilio Orazi
@nl
P106
P31
P496
0000-0002-1660-7013